| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2012 ( Subtotal = $413,650 ) |
| | 2012 | 2012 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44GM090598 | DEVICE FOR AUTOMATING ZEBRAFISH PROCESSING | 000 | 3 | NIH | 8/20/2012 | $413,650 |
|
| Issue Date FY: 2011 ( Subtotal = $396,072 ) |
| | 2011 | 2011 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44GM090598 | DEVICE FOR AUTOMATING ZEBRAFISH PROCESSING | 000 | 2 | NIH | 4/15/2011 | $412,645 |
| | 2011 | 2010 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43GM090598 | DEVICE FOR AUTOMATING ZEBRAFISH PROCESSING | 000 | 1 | NIH | 4/15/2011 | $0 |
| | 2011 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44NS048607 | IN VIVO SCREEN FOR NEUROPROTECTIVE AGENTS | 001 | 4 | NIH | 12/20/2010 | -$2,658 |
| | 2011 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44NS048607 | IN VIVO SCREEN FOR NEUROPROTECTIVE AGENTS | 000 | 3 | NIH | 12/20/2010 | -$8,939 |
| | 2011 | 2007 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44NS048607 | IN VIVO SCREEN FOR NEUROPROTECTIVE AGENTS | 002 | 2 | NIH | 12/20/2010 | -$4,976 |
|
| Issue Date FY: 2010 ( Subtotal = $582,830 ) |
| | 2010 | 2010 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R43GM090598 | DEVICE FOR AUTOMATING ZEBRAFISH PROCESSING | 000 | 1 | NIH | 3/29/2010 | $186,699 |
| | 2010 | 2010 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R43CA150293 | BRAIN CANCER XENOTRANSPLANT MODEL FOR DRUG SCREENING | 000 | 1 | NIH | 5/7/2010 | $191,984 |
| | 2010 | 2010 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44ES017366 | PHASE 2 SBIR: ZEBRAFISH CYTOCHROME P450 ASSAYS FOR ASSESSING DRUG METABOLISM AND | 000 | 4 | NIH | 8/18/2010 | $204,147 |
|
| Issue Date FY: 2009 ( Subtotal = $1,929,590 ) |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44ES017366 | PHASE 2 SBIR: ZEBRAFISH CYTOCHROME P450 ASSAYS FOR ASSESSING DRUG METABOLISM AND | 000 | 2 | NIH | 7/10/2009 | $49,280 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R43GM087923 | NOVEL ASSAY FOR ASSESSING ROS | 000 | 1 | NIH | 6/19/2009 | $193,979 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R43GM087754 | NEW METHOD FOR IDENTIFYING APOPTOSIS DRUG CANDIDATES | 000 | 1 | NIH | 6/19/2009 | $199,439 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44EY016254 | IN VIVO OCULAR ANGIOGENESIS ASSAY | 001 | 4 | NIH | 9/1/2009 | $408,176 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44EY016254 | IN VIVO OCULAR ANGIOGENESIS ASSAY | 000 | 3 | NIH | 6/5/2009 | $49,280 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R43ES017590 | HIGH-CONTENT ANALYSIS TOOLS FOR DEVELOPMENTAL TOXICITY SCREENS IN ZEBRAFISH | 000 | 1 | NIH | 9/11/2009 | $203,224 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44NS048607 | IN VIVO SCREEN FOR NEUROPROTECTIVE AGENTS | 001 | 4 | NIH | 9/16/2009 | $75,518 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44EY015335 | A NEW MODEL FOR EYE DISEASE | 000 | 4 | NIH | 6/5/2009 | $12,320 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44EY015335 | A NEW MODEL FOR EYE DISEASE | 000 | 4 | NIH | 6/5/2009 | $12,320 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44ES017366 | PHASE 2 SBIR: ZEBRAFISH CYTOCHROME P450 ASSAYS FOR ASSESSING DRUG METABOLISM AND | 001 | 3 | NIH | 9/7/2009 | $425,838 |
| | 2009 | 2009 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139-1295 | MIDDLESEX | USA | R44NS048607 | IN VIVO SCREEN FOR NEUROPROTECTIVE AGENTS | 000 | 4 | NIH | 8/25/2009 | $300,216 |
|
| Issue Date FY: 2008 ( Subtotal = $2,390,624 ) |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43GM083366 | ZEBRAFISH CYTOCHROME P450 ASSAYS FOR ASSESSING DRUG METABOLISM AND DRUG SAFETY | 000 | 1 | NIH | 4/1/2008 | $160,671 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43HL088790 | NEW WHOLE ANIMAL ELISA FOR ANGIOGENIC DRUG SCREENING | 000 | 1 | NIH | 8/31/2008 | $135,227 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43MH086086 | IN VIVO ZEBRAFISH GFAP ELISA FOR NEUROTOXICITY | 000 | 1 | NIH | 9/16/2008 | $203,147 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43GM085892 | IN VIVO ZEBRAFISH TYROSINE KINASE ELISA | 000 | 1 | NIH | 9/24/2008 | $201,382 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43GM085983 | NEW MODELS FOR ASSESSING EFFECTS OF CONTRACTILITY | 000 | 1 | NIH | 9/24/2008 | $193,595 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44DC007767 | ZEBRAFISH SCREEN FOR OTOTOXIC AND OTOPROTECTIVE AGENTS | 000 | 4 | NIH | 9/5/2008 | $194,683 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44EY016254 | IN VIVO OCULAR ANGIOGENESIS ASSAY | 000 | 3 | NIH | 9/11/2008 | $334,807 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44NS048607 | IN VIVO SCREEN FOR NEUROPROTECTIVE AGENTS | 000 | 3 | NIH | 8/7/2008 | $352,818 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43CA139967 | METHOD FOR IDENTIFYING CANCER STEM CELLS | 000 | 1 | NIH | 9/24/2008 | $192,874 |
| | 2008 | 2008 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44ES017366 | PHASE 2 SBIR: ZEBRAFISH CYTOCHROME P450 ASSAYS FOR ASSESSING DRUG METABOLISM AND | 000 | 2 | NIH | 9/26/2008 | $421,420 |
|
| Issue Date FY: 2007 ( Subtotal = $1,456,037 ) |
| | 2007 | 2007 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43AR055390 | ZEBRAFISH MUSCULAR DYSTROPHY MODEL FOR DRUG SCREENING | 000 | 1 | NIH | 8/17/2007 | $161,810 |
| | 2007 | 2007 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44NS048607 | IN VIVO SCREEN FOR NEUROPROTECTIVE AGENTS | 000 | 2 | NIH | 7/23/2007 | $362,566 |
| | 2007 | 2007 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44EY016254 | IN VIVO OCULAR ANGIOGENESIS ASSAY | 000 | 2 | NIH | 9/25/2007 | $202,041 |
| | 2007 | 2007 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44EY015335 | A NEW MODEL FOR EYE DISEASE | 000 | 4 | NIH | 9/18/2007 | $158,186 |
| | 2007 | 2007 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44DC007767 | ZEBRAFISH SCREEN FOR OTOTOXIC AND OTOPROTECTIVE AGENTS | 000 | 3 | NIH | 8/23/2007 | $406,935 |
| | 2007 | 2007 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43MH082456 | ZEBRAFISH MODEL FOR IDENTIFYING P-GLYCOPROTEIN INHIBITORS | 000 | 1 | NIH | 8/8/2007 | $164,499 |
|
| Issue Date FY: 2006 ( Subtotal = $1,108,996 ) |
| | 2006 | 2006 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44EY015335 | A NEW MODEL FOR EYE DISEASE | 000 | 3 | NIH | 9/22/2006 | $438,978 |
| | 2006 | 2006 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43NS058251 | BRAIN CANCER ZEBRAFISH XENOTRANSPLANT MODEL FOR DRUG SCREENING | 000 | 1 | NIH | 9/9/2006 | $168,689 |
| | 2006 | 2006 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44DC007767 | ZEBRAFISH SCREEN FOR OTOTOXIC AND OTOPROTECTIVE AGENTS | 000 | 2 | NIH | 9/7/2006 | $334,767 |
| | 2006 | 2006 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43DK074278 | ZEBRAFISH WOUND HEALING MODEL FOR DRUG SCREENING | 000 | 1 | NIH | 2/10/2006 | $166,562 |
|
| Issue Date FY: 2005 ( Subtotal = $1,230,190 ) (Continued on the next page) |
| | 2005 | 2005 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R43EY016254 | IN VIVO OCULAR ANGIOGENESIS ASSAY | 000 | 1 | NIH | 4/30/2005 | $156,599 |
| | 2005 | 2005 | PHYLONIX PHARMACEUTICALS, INC | 100 INMAN STREET SUITE 300 | CAMBRIDGE | MA | 02139 | MIDDLESEX | USA | R44EY015335 | A NEW MODEL FOR EYE DISEASE | 000 | 2 | NIH | 9/16/2005 | $394,867 |
|
